Home › Major Depressive Disorder › North Carolina
Major Depressive Disorder clinical trials in North Carolina
13 studies for Major Depressive Disorder are looking for participants at sites in North Carolina.
Cities in North Carolina
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Magnolia Clinical Research, LLC, Cary
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 5, 2026 · NCT07284667A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Nov 3, 2026 · NCT07227454A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Magnolia Clinical Research LLC, Cary
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Nov 3, 2026 · NCT07573176Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- New Hope Clinical Research, Charlotte
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 28, 2026 · NCT07226661Study of ALTO-300 in MDD
- Site 287, Rose Hill
- Site 268, Winston-Salem
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Oct 26, 2026 · NCT05922878A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Charlotte
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07196501Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder
- Qortical Clinical Partners, Durham
Recruiting
Ages 22 and older · All sexes · Updated Oct 8, 2026 · NCT07282678Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Charlotte
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Charlotte
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06963021A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- UNC Health Rex, Raleigh
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329CARED : A Novel Rapid Treatment Paradigm for Depression
- Carolina Center for Neurostimulation, Chapel Hill
Recruiting
Ages 18 to 70 · All sexes · Updated Jun 25, 2026 · NCT07507370Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
- University of North Carolina, Chapel Hill, Chapel Hill
RecruitingPhase 4
Ages 18 to 45 · Women · Updated Oct 29, 2025 · NCT06610305A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Hickory
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jan 23, 2025 · NCT06223880From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.